Search

Drug Profiles Catalysts Company Profiles Impact Events Target
Indication Trials KOL Insight Special Reports All

Drug Impact Events

Date Lead
Company
Event Type Approval
Change
Approval
Likelihood
09/19/14 AstraZeneca (AZN) Exenatide Suspension (Weekly) for Diabetes Mellitus, Type II Subscribers Only Subscribers Only     Subscribers Only
09/18/14 Salix (SLXP) Xifaxan for Irritable Bowel Syndrome (IBS) Subscribers Only Subscribers Only     Subscribers Only
09/18/14 Eli Lilly (LLY) Trulicity for Diabetes Mellitus, Type II Subscribers Only Subscribers Only     Subscribers Only
09/18/14 Clarus Therapeutics Rextoro for Hypogonadism Subscribers Only Subscribers Only     Subscribers Only
09/18/14 Halozyme (HALO) PEGPH20 for Pancreatic Cancer Subscribers Only Subscribers Only     Subscribers Only

Upcoming Catalysts

Expected
Date Range
Lead
Company
Drug Expected
Catalyst
09/19/14 Subscribers Only Subscribers Only Company - Earnings Announcement
09/19/14 Subscribers Only Subscribers Only Company - Earnings Announcement
09/19/14 Subscribers Only Subscribers Only Company - Earnings Announcement
09/19/14 Subscribers Only Subscribers Only Trial Data - Top-Line Results
09/19/14 Subscribers Only Subscribers Only Trial Data - Other